Incident Gout Risk Following RZV Administration Not Higher Among Adults 50 Years Or Older, Findings Show

Rheumatology Advisor (9/11, Kuhns) says, “The risk for incident gout following administration of the recombinant zoster vaccine (RZV) was not increased among adults aged 50 years or older,” researchers concluded in a retrospective safety study. Published in Seminars in Arthritis & Rheumatism, the findings show that “the risk of gout following RZV exposure did not change relative to the primary analysis in models adjusted for seasonality or restricted to the pre-COVID-19 pandemic era, in dose-specific analyses limited to the first or second dose, or when limiting the gout incidence lookback period to 1 year instead of 2.”